Engflag

Jardin-D

Quick links to important sections

Jardin-D

Jardin-D_EN

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Jardin-D

Quick Facts

Property Description
Active Ingredient Desloratadine
Form Oral tablet, syrup, orally disintegrating tablet (ODT)
Pharmacological Class Second-Generation Antihistamine
General Purpose Mitigating symptoms of allergic hypersensitivity
Origin Synthetic compound (active metabolite)

What Type of Medicine is Jardin-D and How is it Classified?

Jardin-D is a pharmacological agent containing the single active ingredient desloratadine. This medicine belongs to the class of second-generation antihistamines and is officially classified as a highly selective Histamine H1 Receptor Antagonist. Desloratadine is a synthetic compound that represents the biologically active metabolite of the older drug loratadine. This derivation is a differentiating factor, as the compound has enhanced receptor binding affinity, contributing to its effective symptom management with an overall low potential for central nervous system effects.

Desloratadine: Composition and Available Forms

The composition of Jardin-D is based entirely on the active substance desloratadine, combined with the necessary inert pharmaceutical excipients required for stability. As a single-ingredient product, its primary action is focused solely on its antihistaminic properties. The medicine is designed for oral administration and is offered in several common dosage forms, typically including the standard oral tablet, a liquid syrup preparation, and an orally disintegrating tablet (ODT). The availability of liquid forms is a unique feature that ensures flexibility in administration for patients who may have difficulty swallowing.

What is the General Therapeutic Principle of Jardin-D?

The general therapeutic principle of Jardin-D is to mitigate the physical symptoms that arise from allergic hypersensitivity by interrupting the action of histamine. It achieves an anti-allergic effect by selectively preventing histamine from binding to its target sites in the body. Furthermore, desloratadine is characterized as a non-sedating agent. This selective peripheral action allows the compound to provide relief for conditions characterized by symptoms like sneezing, itching, or watery eyes.

What side effects are possible with Jardin-D?

Possible Side Effects and Safety Information for Jardin-D

The safety profile of Jardin-D is formally documented by government regulatory authorities, classifying reported adverse reactions by frequency and potential severity.

Adverse Reaction Classification

Side effects are categorized based on the estimated rate of occurrence, using the following framework:

Frequency Examples of Documented Adverse Reactions
Very Common (ge 1/10) Headache, Nausea, Upper respiratory tract infection
Common (ge 1/100 to < 1/10) Dizziness, Fatigue, Diarrhea, Peripheral edema
Rare (ge 1/10,000 to < 1/1,000) Severe hepatic dysfunction, Angioedema

Adverse reactions are also grouped by the System-Organ Class (SOC) affected, including Nervous System Disorders, Gastrointestinal Disorders, and Vascular Disorders.

Serious Adverse Reactions

The official labeling identifies certain rare but clinically significant events. These Serious Adverse Reactions include, but are not limited to, Angioedema and Severe hepatic dysfunction. These reactions represent high-alert events that are formally documented in regulatory safety summaries.

Safety Restrictions and Monitoring

Jardin-D use is subject to specific constraints regarding patient health, which are explicitly stated in the regulatory documentation:

  • Contraindications: The medicine is contraindicated in cases of known hypersensitivity to the drug or in patients with severe hepatic impairment (Child-Pugh Class C).
  • Renal Function: Use is generally not recommended or restricted for patients with estimated glomerular filtration rates (eGFR) below a specific, low threshold (e.g., < 30 mL/min/1.73 m^2).
  • Monitoring Requirements: The official label requires monitoring of liver enzyme levels and periodic renal function assessment prior to and during treatment.

For older adults, there is documented data suggesting an increased risk of reactions such as hypotension and peripheral edema.

This information represents the factual risk and limitation data established by authoritative government regulatory bodies.

Overdose and Emergency Response

Overdose Map: Overdose and when to seek help — official regulatory information for Jardin-D

Overdose scope

Domain Official Regulatory Statement
Documented Overdose Presentations The adverse event profile is similar to therapeutic doses (e.g., headache, somnolence), but the magnitude of effects can be higher. Severe post-marketing outcomes include seizures, tachycardia, palpitations, and signs of hepatotoxicity (elevated liver enzymes, hepatitis).
Physiological Systems Affected (as stated in label) Nervous System, Cardiovascular System, Hepatobiliary System.
Dose-related or Exposure-related Factors Doses up to 45 mg (nine times the clinical dose) in trials showed no clinically relevant effects.
Population-specific Overdose Notes Paediatric population: The magnitude of adverse effects may be higher, with specific post-marketing reports of cardiac complications such as QT prolongation, arrhythmia, and bradycardia.
Emergency-response statements Management should consider standard measures to remove unabsorbed active substance. Symptomatic and supportive treatment is recommended.
When immediate medical help is required Call your doctor or get medical attention right away.

Overdose classifications (high-level)

Classification Aspect Official Regulatory Statement
Severity classification Defined by the potential for severe, life-threatening events reported post-marketing, such as seizures and cardiac effects, which mandate immediate professional intervention.
Regulatory basis Based on the Overdose/Treatment of Overdose sections in regulatory documents (e.g., EMA SmPCs and FDA Prescribing Information).
Overdose-context constraints No specific antidote is known. The compound is not eliminated by haemodialysis.

Resulting overdose structure

Official overdose statements:

  • In case of overdosage, the required action is to call your doctor or get medical attention right away.
  • Overdosage may present with seizures, tachycardia, and hepatitis as reported in post-marketing data.
  • No specific antidote is known; treatment is limited to symptomatic and supportive measures.
  • Specific cardiac risks like QT prolongation have been noted in children in post-marketing reports.
  • Desloratadine is not eliminated by haemodialysis.

Connection to the overall overdose profile (2–4 sentences): Regulatory documentation defines the overdose profile by documenting the potential for severe manifestations, including nervous system and cardiac effects, alongside the absence of a specific countermeasure. This profile mandates that individuals seek immediate medical attention, as required supportive treatment is the only documented course of action.

Therapeutic Uses of Jardin-D

What Jardin-D Treats: Main Uses and Benefits

Jardin-D is generally used to provide supportive symptomatic relief for conditions involving episodic or fluctuating manifestations, primarily allergic rhinitis (hay fever) and Chronic Idiopathic Urticaria (CIU), or chronic hives. It is applied across therapeutic domains where additional symptomatic support is needed to address symptom clusters that may become intense or disruptive.

For allergic rhinitis, it is relevant for easing symptoms related to heightened physiological activity, such as frequent sneezing, watery nasal discharge (rhinorrhea), nasal itching, and irritating ocular symptoms. In the context of skin conditions, it is commonly used to help manage symptoms related to pronounced, generalized itching (pruritus) and assists with managing the presence of hives.

This symptomatic assistance contributes to improved comfort during periods of heightened symptoms. The application of this medication supports the maintenance of a sense of stability when allergic symptoms are more noticeable, supporting the patient during difficult episodes by easing the overall symptom burden.

Quick Fact: Relief for Allergic Discomfort

Indication Area Primary Symptoms Addressed Typical Contexts of Use
Allergic Rhinitis Sneezing, Itchy/Watery Eyes, Runny Nose Seasonal and Year-Round Symptom Control
Chronic Urticaria Pronounced Itching (Pruritus), Hives/Welts Managing Chronic or Recurrent Skin Episodes

Regulatory References

  1. NIH DailyMed Label

Eligibility and Restrictions for Use

The eligibility for Jardin-D (desloratadine) is governed by official regulatory documentation that defines specific population groups for whom use is either approved, restricted, or contraindicated.

Contraindicated Populations

Jardin-D is strictly contraindicated for individuals with a known hypersensitivity to the active ingredient, desloratadine, or its parent compound, loratadine. Use is also prohibited in patients with certain excipient intolerances, such as hereditary problems of galactose intolerance, depending on the specific product formulation.

Age-Related Eligibility

The medicine is approved for adults and adolescents 12 years of age and older in the tablet form. The oral solution form is approved for children starting from 6 months of age. Use is not recommended for infants below 6 months, as safety and efficacy have not been established. The tablet formulation is not established for children under 12 years.

Conditional Use and Restrictions

Use is permitted but requires caution in patients diagnosed with severe renal impairment or hepatic impairment; official guidance recommends a reduced frequency of use for these adults. Furthermore, Jardin-D should be administered with caution in patients who have a medical or familial history of seizures. Finally, use is not recommended during pregnancy or lactation due to a lack of established safety and the excretion of the substance into breast milk.

What should I know about interactions with other medicines?

Drug-Drug Interaction Profile

Co-administration with strong metabolic inhibitors, such as Ketoconazole (an antifungal agent) and Erythromycin (an antibiotic), has been studied in regulatory trials. These studies reported a pharmacokinetic interaction resulting in increased plasma concentrations ( AUC and C max) of desloratadine and its active metabolite. However, official regulatory documents state that these increases in exposure were not associated with any clinically relevant changes in the overall safety profile. No other specific medicines are listed in primary regulatory documents as requiring mandatory dose separation or being contraindicated due to interaction mechanisms.

Administration Context

Jardin-D has no documented interaction with food, and regulatory documents confirm it may be administered with or without a meal. Regarding alcohol, controlled pharmacology trials officially documented that desloratadine did not potentiate the impairment of psychomotor performance caused by alcohol consumption.

Physiological Exposure Notes

Official labeling provides information on population-specific alterations in drug clearance. Patients with Severe Renal Impairment show reduced clearance leading to an approximate 2.5-fold increase in drug exposure ( AUC). Similarly, those with Hepatic Impairment show a reduced clearance resulting in an approximate 2.4-fold increase in exposure. Furthermore, a subset of the general population classified as poor metabolizers is officially noted to exhibit a median AUC that is approximately mathbf6-fold greater than that observed in typical metabolizers.

Mechanism of Action

Jardin-D is a combination pharmaceutical product containing two distinct active molecular entities: desloratadine and montelukast. The primary mechanism of desloratadine is as a selective antagonist of peripheral histamine H1 receptors (H1).

Desloratadine competes with endogenous histamine for binding sites on the H1 receptor, thereby preventing histamine-mediated receptor activation. This inhibition of the H1 receptor curtails the intracellular signaling cascade initiated by histamine binding, which modulates the physiological consequences of mast cell degranulation.

Montelukast functions as a selective leukotriene receptor antagonist (LTRA). Its molecular target is the cysteinyl leukotriene receptor type 1 (CysLT1) located on respiratory airway smooth muscle cells and other pro-inflammatory cells. Montelukast binds to the CysLT1 receptor, preventing the actions of cysteinyl leukotrienes (LTC4, LTD4, and LTE4). This antagonism blocks the receptor-mediated pathway that normally leads to the promotion of cellular activity, resulting in the system-level modulation of respiratory smooth muscle tone and vascular permeability.

Dosage and Administration Information

How to Use Jardin-D

Jardin-D (desloratadine) is administered solely via the oral route, with dosing structured around a standardized regimen that must be followed for effective use. The medicine is taken once daily regardless of the specific form used, which includes the 5 mg oral tablet, a liquid oral solution, and the orally disintegrating tablet (ODT). Administration is flexible in relation to food and can be taken with or without meals.

Official Dosing Patterns

the standard adult dose for those 12 years and older is 5 mg taken once every 24 hours. The official instructions for use mandate a different frequency for patients with compromised kidney or liver function; for adults with severe hepatic or renal impairment, the dose is typically adjusted to 5 mg every other day to manage systemic exposure.

Population Group Standard Daily Dose Frequency
Adults (ge 12 years) 5 mg Once daily
Adults with Severe Impairment 5 mg Every other day

Administration and Duration Principles

Specific procedural requirements apply to certain forms. The liquid oral solution must be measured using a calibrated dosing tool, such as a syringe or dropper. For the ODT, the tablet is removed from its packaging with dry hands and placed on the tongue to dissolve and be swallowed with saliva, not requiring water. The duration of use is not fixed but is generally dictated by the pattern of the underlying condition: treatment for Intermittent Allergic Rhinitis can be discontinued when symptoms resolve and reinitiated upon recurrence, while Persistent Allergic Rhinitis requires continuous administration. If a dose is missed, it should be taken when remembered, but never doubled if it is close to the next scheduled dose.

Recent Clinical Evidence

The research base for Jardin-D, studied for conditions like allergic rhinitis and chronic idiopathic urticaria, is primarily built upon large, randomized, placebo-controlled trials (RCTs). For allergic rhinitis (hay fever), studies focused on adults and adolescents (typically individuals 12 years of age and older) and examined short-term symptom changes over periods generally up to four weeks. Researchers monitored changes in the Total Symptom Score, covering nasal and ocular discomfort, as well as outcomes reflecting daily functioning and sleep interference. Studies reported patterns of measured changes in symptom scores compared against placebo.

For chronic urticaria (chronic hives), the research base similarly relies on randomized, controlled trials, typically lasting up to six weeks. These trials examined outcomes related to physical discomfort by tracking the Urticaria Activity Score (UAS), which measures the severity of itching (pruritus) and the size of wheals. Findings indicated measured changes in primary symptoms and associated measures of sleep interference. Research was also observed in patient cohorts studied for doses higher than the standard amount. Specific studies examined cohorts of patients with allergic rhinitis who also had concurrent mild-to-moderate asthma.

The majority of high-quality, controlled trials focused on short-term to intermediate scenarios, meaning long-term outcomes are not fully established by controlled, randomized evidence. Data for certain younger age groups remains insufficient. Additionally, comparative evidence is lacking, meaning there are few head-to-head randomized trials designed to show clear differences against all other available medications in the same class. The certainty remains low regarding studies examining increasing the dose beyond the standard amount for patients with chronic hives whose symptoms are not managed by the initial dose.

Key Studies & References

  1. CLARINEX (desloratadine) Tablets Official U.S. Prescribing Information (DailyMed)

Frequently Asked Questions (FAQ)

Common questions about Jardin-D (FAQ)

Q: Why is Jardin-D sometimes confused with other treatments?

According to official regulatory documents, the active ingredient in Jardin-D, desloratadine, is described as the active metabolite of the older medicine, loratadine. This chemical relationship is the main reason for the association between the two treatments. Official safety warnings and restrictions often reference both compounds.

Q: Do the side effects of Jardin-D usually go away after the first week?

Regulatory documents list the side effects but do not provide specific information on the typical duration for common effects like fatigue or nausea. Some clinical studies measure average symptom changes over the first week of treatment. If ongoing side effects are a concern, a discussion with a healthcare provider may be helpful.

Q: Can Jardin-D cause problems with my liver or kidneys?

Official regulatory summaries list severe hepatic dysfunction (serious liver problems) as a rare but documented adverse reaction. Furthermore, official instructions advise adjusting the dose frequency for adults with severe hepatic (liver) or renal (kidney) impairment. This is because the drug is cleared differently in these conditions.

Q: How long does it usually take to notice the described effects of Jardin-D?

Pharmacokinetic data indicates that the medicine reaches its peak concentration in the bloodstream approximately 3 hours after administration. For conditions like chronic hives, some clinical trial results report the mean reduction in itching was measured over the first week of treatment. Individual responses to treatment mean that the time to observe symptom relief can vary.

Q: What happens if I stop taking Jardin-D suddenly?

Official guidance for conditions like Intermittent Allergic Rhinitis states that treatment can be discontinued when symptoms resolve. Regulatory documents do not provide specific details on any potential effects associated with the sudden stop of continuous (persistent) treatment. Information regarding any change to an ongoing persistent regimen is typically provided by a healthcare professional.

Q: Is Jardin-D something I need to take indefinitely?

Official guidance indicates that the duration of use depends on the condition being treated. Treatment for conditions like Intermittent Allergic Rhinitis (symptoms come and go) can be stopped when symptoms are gone. However, treatment for Persistent Allergic Rhinitis (long-term symptoms) or Chronic Urticaria (hives) may require continuous administration.

Q: What should I do if I miss a scheduled dose of Jardin-D?

The official instructions advise that if a dose is missed, it should be taken when remembered. However, it is explicitly stated that a dose must never be doubled to make up for a missed one if it is close to the next scheduled time.

Q: Does Jardin-D affect the ability to drive or operate machinery?

Official documents state that the medicine is described as having no or negligible influence on the ability to drive and use machines. This is based on clinical trials conducted. However, official guidance suggests patients assess their individual response before engaging in activities that require mental alertness, as individual reactions can vary.

Q: Is it normal to feel slightly nauseous when starting Jardin-D?

Nausea is listed in official safety summaries as a Very Common side effect, meaning it was one of the more frequently observed effects in clinical studies. This indicates that it is one of the more frequently reported effects in regulatory documents.

Q: Are there any long-term side effects associated with Jardin-D use?

The official research base for Jardin-D primarily involves short-term to intermediate-term trials, typically lasting up to four to six weeks. Therefore, the certainty remains low regarding evidence for long-term outcomes, as they are not fully established by controlled, randomized studies.

Q: Do I need any special tests before starting treatment with Jardin-D?

The official label requires monitoring of liver enzyme levels and a periodic assessment of kidney function for patients. These assessments are required to monitor key functions prior to and during the treatment course.

Q: Is Jardin-D a controlled substance?

Jardin-D's active ingredient, desloratadine, is a second-generation antihistamine. It is not classified as a controlled substance by U.S. regulatory authorities.

Q: Is there any risk of becoming dependent on Jardin-D?

Jardin-D is a highly selective H1 receptor antagonist, a type of antihistamine. Its pharmacological class and mechanism of action do not indicate a risk for dependence in official regulatory documents.

Q: Why do some people report feeling tired after taking Jardin-D?

Official regulatory safety summaries list both Fatigue and Somnolence (drowsiness) as common side effects of Jardin-D. While it is classified as non-sedating compared to older antihistamines, these effects were still reported in clinical trials.

Q: Does Jardin-D affect sleep patterns?

Official regulatory documents list Insomnia (difficulty sleeping) as a very rare adverse reaction. Additionally, clinical trials for Jardin-D included the potential for sleep interference as an outcome that was monitored.

Q: What are the official warnings listed for Jardin-D?

Official warnings and precautions listed in the regulatory labeling include the potential for hypersensitivity reactions (such as rash or severe swelling) and the need for caution in patients with a history of seizures.

Q: How is the safety profile of Jardin-D described in regulatory documents?

Official regulatory documents generally describe the safety profile as favorable. They note that undesirable effects were reported in a small percentage of patients (e.g., 3%) in excess of those treated with a placebo during clinical trials.

Q: Do studies suggest Jardin-D works better for certain types of patients?

Official research documentation indicates that there is a lack of head-to-head comparative evidence against all other similar medications. Furthermore, the certainty remains low regarding evidence for increasing the dose above the standard amount for patients whose symptoms are not managed by the initial dose.

Q: What happens if a child accidentally takes Jardin-D?

Official documents advise that in case of accidental overdose, seeking emergency medical attention or contacting a poison control center is necessary. It is important that all medication is stored out of the sight and reach of children.

Q: When was Jardin-D first approved for use?

The active ingredient in Jardin-D, desloratadine, received its initial approval from the U.S. Food and Drug Administration (FDA) in February 2002.

Q: Are there specific monitoring requirements for patients taking Jardin-D?

Yes, the official label requires monitoring of liver enzyme levels and periodic renal (kidney) function assessment for patients. This testing is advised to be performed both prior to and during the treatment period.

Q: Does taking Jardin-D require changes to diet or lifestyle?

Official regulatory documents state that the medicine has no documented interaction with food, meaning it can be taken with or without a meal. There are no specific, general lifestyle changes (such as avoiding sun exposure or specific activities) mandated in the core documents.

How should Jardin-D be stored and disposed of?

How to Store and Dispose of Jardin-D

The storage of Jardin-D (desloratadine) must adhere to specific regulatory requirements to maintain product stability and ensure public safety.

Storage Condition Official Requirement
Temperature Store at controlled room temperature, defined as 20 C to 25 C (68 F to 77 F), with permitted excursions between 15 C and 30 C (59 F and 86 F).
Environment Keep the medicine in its original container, tightly closed, and protect it from moisture and excessive heat.
Child Safety The medicine must be stored out of the sight and reach of children in a safe, locked location.

For disposal, unused or expired Jardin-D must not be discarded via wastewater or general household waste. The official instructions require asking a pharmacist how to properly throw away any medicine no longer needed, typically by returning it through a formal pharmaceutical collection scheme.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Jardin-D found in:

A-Z Index: